All articles tagged with #schedule iii
Trump is considering reclassifying marijuana as a Schedule III drug, which would reduce penalties, and has expressed support for marijuana legalization in Florida, though he has not committed to a decision yet. The move is controversial among his base, with some opposing it to protect public spaces.
Cannabis stocks surged after rumors of the DEA potentially rescheduling marijuana to Schedule III, prompting significant gains for industry leaders like Curaleaf Holdings, Canopy Growth, and Aurora Cannabis. If the rescheduling occurs, it could lead to lower taxes for cannabis companies and more competitive prices for consumers. The Benzinga Cannabis Capital Conference in Florida will provide a platform for industry networking and growth opportunities.
The Department of Health & Human Services is recommending to the Drug Enforcement Agency to re-categorize marijuana from a Schedule I drug to a Schedule III drug, which would place it in the same group as anabolic steroids. State Senator Gregg Schmedes expresses concerns about pediatric cannabis exposure, while CEO of Smokin' Dispensaries highlights the medical benefits. The impact on New Mexico and the cannabis industry, as well as the timeline for any changes, will be discussed in a news segment tonight.
The U.S. Department of Health and Human Services has requested the Drug Enforcement Agency (DEA) to consider loosening restrictions on marijuana by moving it from a Schedule I to a Schedule III drug classification. This could have significant implications for the cannabis industry, including new tax opportunities, potential for interstate commerce, expanded research, and increased investor interest. However, federal legalization and access to banking services for the industry still require further legislative action. The DEA is expected to make a decision before the 2024 presidential election.
The Department of Health and Human Services (HHS) has recommended that cannabis be moved from Schedule I to Schedule III of the Controlled Substances Act, marking a historic acknowledgment that cannabis has been misclassified. While this recommendation does not immediately legalize marijuana or impact the cannabis industry significantly, it could lead to the elimination of the 280e tax code, which currently hinders profitability for cannabis businesses. This change may also attract new sources of capital and lending to the industry. Additionally, rescheduling could prompt the Toronto Stock Exchange and potentially other exchanges to accept U.S.-based cannabis companies. The HHS recommendation may also encourage Congress to take further action on cannabis reform. Overall, this announcement brings the United States closer to a post-prohibition reality.
The Department of Health and Human Services (HHS) has recommended to the Drug Enforcement Administration (DEA) that marijuana be reclassified as a lower-risk, Schedule III controlled substance, a move that could lead to a significant shift in federal policy on cannabis. While this would not outright legalize marijuana at the federal level, it could boost the regulated marijuana industry in states where it is legal and facilitate more scientific research into the drug's effects. The recommendation aligns with President Biden's efforts to reshape marijuana policies, and if accepted by the DEA, it would mark a historic step in cannabis reform. However, advocates for full legalization argue that the recommendation doesn't go far enough and that cannabis should be treated similarly to tobacco and alcohol.
The Biden administration's Department of Health and Human Services (HHS) has recommended that the Drug Enforcement Agency (DEA) loosen federal restrictions on marijuana by moving it from Schedule I to Schedule III under the Controlled Substances Act (CSA). This recommendation, based on a review conducted by the Food and Drug Administration (FDA), could be the biggest change in federal drug policy in decades. However, the HHS stopped short of advising complete removal of marijuana from the CSA. The DEA has the final authority to schedule or reschedule a drug, and it will now initiate its review. Rescheduling cannabis to Schedule III could have significant implications for the cannabis industry, including lower federal taxes and easier access to banking services. It could also facilitate research on cannabis and the development of cannabis-based pharmaceuticals. However, advocates argue that rescheduling alone does not address the issue of criminalization.
The U.S. Department of Health and Human Services (HHS) has recommended that marijuana be reclassified as a Schedule III drug, according to a letter addressed to the Drug Enforcement Agency (DEA) administrator. Currently classified as a Schedule I drug, the move would ease restrictions on marijuana and align with the legalization efforts in about 40 U.S. states. The DEA confirmed receiving the letter and stated that it will initiate a review. Cannabis companies and advocates welcomed the HHS recommendation, citing the need to end the harm caused by marijuana prohibition.